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Abstract
Until now, no specific therapies are available to inhibit pancreatic fibrosis, a constant pathological
feature of chronic pancreatitis and pancreatic cancer. One major reason is the incomplete
knowledge of the molecular principles underlying fibrogenesis in the pancreas. In the past few years,
evidence has been accumulated that activated pancreatic stellate cells (PSCs) are the predominant
source of extracellular matrix (ECM) proteins in the diseased organ. PSCs are vitamin A-storing,
fibroblast-like cells with close morphological and biochemical similarities to hepatic stellate cells
(also known as Ito-cells). In response to profibrogenic mediators such as various cytokines, PSCs
undergo an activation process that involves proliferation, exhibition of a myofibroblastic phenotype
and enhanced production of ECM proteins. The intracellular mediators of activation signals, and
their antagonists, are only partially known so far. Recent data suggest an important role of enzymes
of the mitogen-activated protein kinase family in PSC activation. On the other hand, ligands of the
nuclear receptor PPARγ (peroxisome proliferator-activated receptor γ) stimulate maintenance of
a quiescent PSC phenotype. In the future, targeting regulators of the PSC activation process might
become a promising approach for the treatment of pancreatic fibrosis.
Review
Excessive production of connective tissue molecules form-
ing the extracellular matrix (ECM) is a pathological proc-
ess relevant to diseases of many organ systems, including
liver, lung, kidney, bowel and pancreas. The resulting
fibrosis frequently leads to a progressive loss of specific
organ functions. In the past two decades, fibrogenesis has
been intensively studied by a large number of laborato-
ries, and a great deal of scientific information has been
accumulated regarding the pathogenesis of fibrosis in var-
ious organs. Until a few years ago, pancreatic fibrosis,
however, remained an exception: although known for a
long time as a central pathological feature of both chronic
pancreatitis and pancreatic cancer [1,2], its cellular and
molecular basics remained obscure. This situation has
changed significantly since the identification of a fibrob-
last-like cell type in the pancreas with close similarities to
hepatic stellate cells (HSCs; also called Ito cells) [3,4], the
predominant source of ECM in the fibrotic liver [5,6]. In
the meantime, it has become increasingly clear that these
stellate cells of the pancreas (named pancreatic stellate
cells; PSCs) are the principle effector cells in pancreatic
fibrosis. In the following sections, I will focus on (I) the
current understanding of the role of PSCs in fibrogenesis,
(II) extracellular signals involved in PSC activation, (III)
intracellular mediators of activation signals in PSCs, (IV)
future directions of research, and (V) activated PSCs as a
target for antifibrotic therapies.
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Pancreatic stellate cells and their role in pancreatic 
fibrogenesis
Both chronic pancreatitis and pancreatic cancer are
accompanied by an organ fibrosis [1,2]. The progressive
replacement of pancreas-specific tissue by ECM-rich con-
nective tissue leads to the development of an exocrine and
endocrine insufficiency of the gland. So far, specific ther-
apies to prevent, retard or even reverse this process are not
available.
Fibroblast activation has been reported to be a common
event in pancreatitis already more than a decade ago [7-9],
but the basic matrix producing cell type in the pancreas
remained to be identified. In 1997, Saotome et al. [10]
described the isolation of periacinar fibroblast-like cells
from human pancreas. The cells displayed some character-
istics of activated myofibroblasts, e.g. expression of α-
smooth muscle actin (α-SMA) and synthesis of ECM pro-
teins. One year later, Bachem et al. [3] and Apte et al. [4]
found that vitamin A-storing cells resembling hepatic stel-
late cells can be isolated from human and rat pancreas. In
the healthy organ, PSCs comprise about 4% of all pancre-
atic cells and show a periacinar distribution. They can be
identified by the presence of retinoid-containing cytoplas-
mic lipid droplets and by immunostaining for cytoskele-
tal proteins such as desmin and glial fibrillary acidic
protein [4]. In culture, pancreatic stellate cells readily
grow [4] and change from a quiescent phenotype to a
myofibroblast-like cell expressing α-SMA and producing
large amounts of the ECM proteins collagen type I and III,
fibronectin as well as laminin [3]. This activation process
is accompanied by a loss of the characteristic retinoid-
containing fat droplets [3,4]. Together, these in vitro data
gave rise to the hypothesis that PSCs might play a pivotal
role in pancreatic fibrogenesis.
In the meantime, this hypothesis has been supported by
the results of several in vivo studies using experimental
models of pancreatic fibrosis: Infusion of trinitrobenzene
sulfonic acid (TNBS) into the pancreatic duct of rats
causes a pancreatic necroinflammation followed by fibro-
sis [11]. In TNBS-treated rats, areas of pancreatic fibrosis
colocalized with α-SMA-positive cells, suggesting the pres-
ence of activated PSCs. Furthermore, dual staining tech-
niques indicated that these α-SMA-positive cells were the
main source of collagen in the fibrotic pancreas [12].
Importantly, very similar data were obtained when pan-
creatic tissue from patients with chronic pancreatitis was
analyzed [12]. Another well-established model of fibro-
genesis involves the administration of a single intrave-
nous dose of dibutyltin dichloride (8 mg/kg body
weight), resulting in the development of a chronic pancre-
atitis associated with fibrosis [13]. Time course studies of
DBTC-induced chronic pancreatitis revealed an early acti-
vation of PSCs that preceded development of fibrosis
[14]. In mice, repeated intraperitoneal application of sup-
raphysiological cerulein doses causes a pancreatic injury
and, subsequently, fibrosis [15,16]. In agreement with the
data mentioned above, collagen gene expression was
colocalized to PSCs [16]. Overexpression of transforming
growth factor-beta (TGF-β) 1 in transgenic mice has been
shown to be associated with increasing deposition of ECM
in the pancreas. In parallel with the development of fibro-
sis, the number of PSCs in the pancreas increased [17].
Recently, it has also been suggested that PSCs contribute
to regeneration early after acute necrotising pancreatitis in
humans [18].
Together, in vitro and in vivo data suggest that PSCs are
essentially involved in the development of pancreatic
fibrosis.
Extracellular signals involved in pancreatic stellate cell 
activation
Based on the results of various recent studies, extracellular
factors involved in PSC activation may be divided into
two major groups: (I) cytokines/growth factors [3,19-22]
and (II) ethanol and its metabolites, most of all acetalde-
hyde [23].
Cytokines stimulating PSC activation include platelet-
derived growth factor (PDGF) [3,19,21,22], the TGF-β
family members TGF-β1 [3,19,21,22] and activin A (24),
TGF-alpha [3,22], basic fibroblast growth factor [3,22],
tumor necrosis factor-α (TNF-α) [22], interleukin (IL)-1
[20] and IL-6 [20]. While TGF-β1 efficiently promotes
ECM synthesis [3,19,21,22], PDGF is considered to be the
most effective mitogen [22]. Furthermore, PDGF also
enhances the migratory capacity of PSCs [25]. Potential
sources of cytokines stimulating PSC activation in the
inflamed pancreas are, for example, activated macro-
phages (secreting TGF-β1) [26], platelets (containing
PDGF and TGF-β1) [21], and possibly acinar cells
(expressing, among other cytokines, TNF-α [27], IL-1 and
IL-6 [28]). Importantly, PSCs themselves are capable of
synthesizing cytokines such as TGF-β1 [29,30], activin A
[24] and IL-1 [31]. These observations suggest the exist-
ence of autocrine loops that may contribute to the perpet-
uation of PSC activation after an initial exogenous signal,
thereby promoting the development of fibrosis.
Recent studies have also implicated the pancreatic renin-
angiotensin system [32,33] in pancreatic fibrogenesis.
Thus, application of the angiotensin-converting enzyme
inhibitor lisinopril [34], as well as the angiotensin II
receptor antagonist candesartan [35], suppressed pancre-
atic inflammation and fibrosis in an animal model of
spontaneously occurring chronic pancreatitis, Wistar
Bonn/Kobori rats. In angiotensin II receptor type 1a-defi-Molecular Cancer 2004, 3:26 http://www.molecular-cancer.com/content/3/1/26
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cient (AT1a(-/-)) mice, pancreatic fibrosis induced by
repeated episodes of acute pancreatitis (following cerulein
injections) was found to be attenuated [36]. In vitro, angi-
otensin II (ATII) stimulates PSC proliferation [37,38] and
induces cell contraction [38].
Cytokines that act as antagonists of PSC activation have
not been systematically studied so far. Recently, it has
been shown that IFN-α protects hepatic stellate cells from
lipid peroxidation by enhancing biological activities
against oxidative stress, resulting in an inhibition of acti-
vation [39]. Furthermore, antiproliferative effects of IFN-
α [40], IFN-β and IFN-γ [41] on HSCs have been reported.
On the other hand, IFN-α also inhibits spontaneous
apoptosis of activated HSCs [40]. The effects of interfer-
ons on pancreatic fibrogenesis remain to be characterized.
Although it is known for a long time that chronic pancre-
atitis, associated with fibrosis, is a serious complication of
alcohol abuse, the pathogenesis of alcoholic pancreatitis
still remains to be fully elucidated [reviewed in [42]]. In
recent studies, the question has been addressed how long-
term alcohol consumption is linked to PSC activation and
fibrosis. It has been proposed that the profibrogenic
effects of ethanol are in part mediated by PSC-activating
proinflammatory cytokines released during episodes of
alcoholic pancreatitis (associated with necroinflamma-
tion) [43]. Furthermore, in vitro data suggest that ethanol
directly acts on PSCs and induces activation [23]: Cul-
tured PSCs respond to ethanol application by increased α-
SMA expression and collagen synthesis. Stimulatory
effects of ethanol were detectable both in already activated
and still quiescent PSCs. The cells express alcohol dehy-
drogenase, indicating that they are capable of ethanol oxi-
dation and generation of its metabolite acetaldehyde.
Very likely, induction of oxidant stress in PSCs contributes
to the profibrogenic effects of ethanol [23]. Although the
exact chain of events linking ethanol abuse to pancreatic
inflammation and PSC activation remains to be
described, it is likely that both direct and indirect
(cytokine-mediated) effects of ethanol on PSCs are
involved in the development of pancreatic fibrosis.
Intracellular transduction of activation signals
In the past two years, analysis of signal transduction path-
ways regulating PSC function has become a focus of atten-
tion. As detailed below, identification of signaling
molecules that play a crucial role in PSC activation is a
promising approach for the development of therapeutic
strategies to inhibit pancreatic fibrosis. It is therefore
envisaged that the systematic elucidation of signaling path-
ways in PSCs will also be one of the most important issues
for future research. So far, research regarding intracellular
signaling in PSCs has focused on two main aspects: the
role of enzymes of the mitogen-activated protein kinase
(MAPK) family and the transcriptional control of PSC
activation.
MAPKs are a family of serine/threonine specific protein
kinases with a wide range of biological functions in the
regulation of fundamental cellular processes, including
gene expression, proliferation and cell survival/apoptotic
cell death [44-46]. In mammalian cells, three major
MAPK families (extracellular signal-regulated kinases
[ERKs], c-Jun N-terminal kinase [JNK] and p38) have been
identified [45], and all of them have recently been studied
with respect to the regulation of PSC activation. The best-
characterized ERKs, ERK 1 and 2, are activated through a
well-established pathway (induced by many growth fac-
tors) that involves, among several other cytosolic pro-
teins, the small G-protein Ras and the serine/threonine-
specific protein kinase Raf-1 [45]. In the process of PSC
activation induced by sustained culture, ERK 1/2 activa-
tion is an early event that precedes exhibition of a myofi-
broblastic phenotype [47]. The strong PSC mitogen PDGF
induces an activation of ERK 1/2, and inhibition of sign-
aling through the Ras-Raf-ERK signaling cascade attenu-
ates PSC proliferation [47-49]. It has also been shown that
exposure of PSCs to ethanol and acetaldehyde is accom-
panied by a fast [50] and long-lasting [51] ERK 1/2
activation.
The other two major MAP kinase pathways, involving JNK
and p38, are well-established mediators of signals
induced by pro-inflammatory cytokines and cellular stres-
sors (e.g., oxidant stress, UV irradiation) [52]. In PSCs,
both JNK and p38 are activated in response to ethanol/
acetaldehyde exposure [50,51]. Inhibition of p38 enzy-
matic activity interferes with ethanol-induced myofibrob-
lastic transdifferentiation of PSCs [51]. The p38 signaling
pathway has also been implicated in the mediation of the
mitogenic PDGF effect and in the induction of PSC activa-
tion induced by sustained culture [53]. Incubation of
freshly isolated PSCs with the JNK inhibitor SP600125
attenuates proliferation of the cultured cells [54]. MAP
kinase pathways have also been shown to be involved in
ATII signaling in PSCs [37,38]. Together, these data sup-
port the hypothesis that MAPKs are key mediators of acti-
vation signals in PSCs.
Two other intracellular signal transduction pathways that
have recently been studied regarding their role in PSC acti-
vation are the phosphatidylinositol 3 (PI 3)-kinase and
the Rho-Rho kinase (ROCK) pathway. The results suggest
that PI 3-kinase activity is required for PDGF-stimulated
PSC migration but not proliferation [49,55]. The Rho-
ROCK pathways was shown to be involved in the activa-
tion process of PSCs in vitro by regulating the actin
cytoskeleton [56].Molecular Cancer 2004, 3:26 http://www.molecular-cancer.com/content/3/1/26
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Cytokine and growth factor receptors exert their effects on
the expression of target genes through signaling cascades
that regulate the activity of a characteristic set of transcrip-
tion factors. Recently, the group of the author has ana-
lyzed the activation profiles of activator protein (AP)-1
[57,58], signal transducer and activator of transcription
(STAT) 3 [59] and nuclear factor (NF)-κB [60,61] in the
course of PSC activation induced by sustained culture. AP-
1 and NF-κB displayed an earlier maximum of DNA bind-
ing activity than STAT3 [62]. Further experiments revealed
that phenotypic transition of PSCs towards myofibrob-
lasts was accompanied by characteristic changes of AP-1
complex composition (increase of the JunD content rela-
tive to the one of JunB) [62]. DNA binding of AP-1 in
PSCs is induced by PDGF, suggesting AP-1 activation as an
important step in the process of PSC activation [47].
In the transduction of TGF-β receptor-derived signals into
the nucleus, Smad transcription factors play a central role
[63,64]. Studies by Ohnishi and co-workers revealed that
TGF-β1 stimulated PSC activation (indicated by increased
α-SMA expression) in a Smad2-dependent manner, while
Smad3 was required for TGF-β1-induced growth inhibi-
tion [65]. Interestingly, exogenous TGF-β1 increased TGF-
β1 mRNA expression in PSCs through an ERK-dependent
but Smad2/3-independent pathway. Together, these data
suggest distinct roles of Smad2-, Smad3- and ERK-
dependent pathways in TGF-β1 regulation of PSC func-
tions. Based on recently published data on HSC biology
[66], it can be hypothesized that Smad7, a negative regu-
lator of TGF-β signaling, might act as a transcriptional
inhibitor of PSC activation, but so far experimental evi-
dence has not been presented.
Recent studies have implicated the nuclear hormone
receptor peroxisome proliferator-activated receptor γ
(PPARγ) in the inhibition of stellate cell activation in liver
[67-69] and pancreas [69]: The PPARγ ligands 15-deoxy-
∆12,14-prostaglandin J2 and troglitazone (an antidiabetic
drug of the thiazolidinedione group) act as antagonists of
PSC activation in vitro that decrease cell proliferation and
expression of α-SMA [70]. In Wistar Bonn/Kobori rats,
troglitazone attenuates pancreatic inflammation and
fibrosis [71]. The antifibrotic effect of the drug, however,
was found to be in part mediated via a PPARγ-independ-
ent mechanism [72]. Thus, the precise role of PPARγ in
pancreatic fibrogenesis remains to be elucidated in further
studies.
Open questions with respect to PSC biology and pathology
While the role of activated PSCs in pancreatic fibrosis is
well established, the physiological functions of their qui-
escent precursors are less well understood. Importantly,
PSCs are not only a source of ECM but also of matrix-
degrading enzymes of the MMP (matrix metalloprotein-
ases) family and their inhibitors (tissue inhibitors of
matrix metalloproteinases, TIMPs). Thus, PSCs have been
shown to secrete MMP-2, MMP-9 and MMP-13 and to
express TIMP-1 and TIMP-2 [73]. It appears therefore
likely that PSCs participate in the regulation of matrix
turnover in the healthy pancreas.
The embryonic origin of PSCs still remains to be deter-
mined. Very recently, Seaberg et al. [74] reported the
clonal identification of multipotent precursors from adult
mouse pancreas that generate neural and pancreatic line-
ages, including β-like cells and pancreatic stellate cells.
With regard to PSC biology, one implication of this pio-
neer study is that PSCs share with exocrine and endocrine
pancreatic lineages a common progenitor cell. Kruse et al.
[75] have described the isolation and culture of undiffer-
entiated pancreatic cells, capable of extended self-renewal
and spontaneous differentiation into cells of all three
germ layers. The relationships between these cells, which
were described as stellate-like cells, and PSCs are currently
unknown and should be further studied using clonal cell
populations.
Until now, the physiological consequences of vitamin A-
storage in PSCs remain unclear. It has recently been
shown by the group of the author that the vitamin A deri-
vate all-trans retinoic acid has complex effects on PSC
function and acts, at least in part, as an antagonist of the
activation process [76]. It is, therefore, tempting to specu-
late that retinoic acids, through the binding to their
nuclear receptors and the regulation of gene expression,
are involved in the maintenance of a quiescent PSC phe-
notype. In this scenario, the loss of retinoids in the course
of PSC activation might be not an epiphenomenon but an
essential prerequisite.
In the past, research regarding PSC biology has almost
exclusively focused on the molecular basics of the activa-
tion process. However, given that participation in regener-
ation after pancreatic injury is an important function of
activated PSCs, it is apparent that a disturbance of the
inactivation or elimination of activated PSCs, rather than
PSC activation itself, is the pathological process that leads
to fibrosis. So far, it has not been systematically studied
whether activated PSCs are capable of returning into a
quiescent stage after fulfilling a repair function. Alterna-
tively, elimination by apoptosis might be important in
terminating the wound-healing response after pancreatic
injury [77].
Finally, work on the complex relationships between PSCs
and pancreatic tumor cells is still in its infancy. Very likely,
activation of PSCs not simply accompanies tumor pro-
gression but plays an active role in this process. Thus, it
has been recently been shown that pancreatic cancerMolecular Cancer 2004, 3:26 http://www.molecular-cancer.com/content/3/1/26
Page 5 of 8
(page number not for citation purposes)
growth and progression is accelerated through complex
functional interactions between carcinoma cells and PSCs
[78]. Furthermore, the increased deposition of connective
tissue in pancreatic carcinoma was suggested to be the
result of a paracrine stimulation of PSCs by cancer cells
[79]. Interestingly, TGF-β1-transfected pancreatic tumor
cells have been demonstrated to induce a rich stroma after
orthotopical transplantation in the nude mouse pancreas
[80]. Considering the established role of TGF-β1 in PSC
activation [3,19,21,22], it appears likely that the cytokine
is a key effector in tumor-associated pancreatic fibrosis. It
is easy to predict that the further analysis of PSC activation
in pancreatic cancer will be an important research area in
the future.
Studies on PSC biology are still hampered by the limited
availibility of primary cells. Possibly, recently established
pancreatic stellate cell lines [81,82] will be helpful in over-
coming this problem.
Therapeutic implications
Given that activated PSCs are the principle effector cells in
pancreatic fibrosis, targeting PSCs might become a prom-
ising therapeutic approach. Principle strategies that can be
envisaged include an interruption/reversion of the activa-
tion process as well as an elimination of activated PSCs,
e.g. through an induction of apoptosis. So far, potential
antifibrotic drugs have been mainly tested in models of
liver fibrosis (reviewed in [83]). The existence of common
mechanisms in the development of liver and pancreatic
Pancreatic stellate cell activation in chronic pancreatitis and pancreatic cancer Figure 1
Pancreatic stellate cell activation in chronic pancreatitis and pancreatic cancer. Pancreatic stellate cells are activated by profi-
brogenic mediators, such as ethanol metabolites and cytokines/growth factors. Perpetuation of stellate cell activation under 
persisting pathological conditions results in pancreatic fibrosis.
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fibrosis (particularly, the key role of activated stellate
cells), however, suggests that at least some of these drugs
may also be effective inhibitors of fibrogenesis in the pan-
creas. In this regard, the efficiency of substances interfer-
ing with the action of stellate cell mitogens (e.g., PDFG),
or cytokines stimulating ECM synthesis (especially TGF-
β), should be tested in animal models of pancreatic fibro-
sis. The inhibitory effects of an angiotensin-converting
enzyme inhibitor [34], as well as an ATII receptor antago-
nists [35], on pancreatic fibrosis need to be further evalu-
ated. Interesting candidates are also cytokines that display
inhibitory effects on hepatic stellate cell activation, such as
interferons.
As described above, studies on the regulation of PSC acti-
vation at the intracellular level have identified key media-
tors of stimulatory and inhibitory signals. Targeting
molecules such as PPARγ, MAP kinases, PI 3-kinase, or
Smad proteins might become an important approach for
the treatment of pancreatic fibrosis in the future. Further
progress in the development of antifibrotic therapies can
be expected from the ongoing elucidation of the molecu-
lar principles of PSC activation.
Conclusions
PSCs play a crucial role in pancreatic fibrogenesis (Figure
1). Ethanol metabolites and cytokines such as PDGF and
TGF-β are key activators of PSCs. The intracellular regula-
tion of PSC activation is incompletely characterized. MAP
kinase signaling cascades are involved in the transduction
of activation signals, while PPARγ ligands induce a quies-
cent PSC phenotype. The recent progress in the under-
standing of the cellular and molecular basics of pancreatic
fibrosis will facilitate the development of therapeutic
strategies to inhibit pancreatic fibrosis.
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